Company news
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) news
Cartesian Therapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Cartesian Therapeutics Announces New Employment Inducement Grants
Press releases & updates
Cartesian Therapeutics Announces New Employment Inducement Grants
October 1, 2026
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
September 28, 2026
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
September 29, 2026
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
June 8, 2026
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
May 26, 2026
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 12, 2026
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
March 9, 2026
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
January 9, 2026
Cartesian Therapeutics Announces New Employment Inducement Grants
January 6, 2026
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
December 18, 2025
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
November 13, 2025
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
October 30, 2025
Cartesian Therapeutics Announces New Employment Inducement Grant
October 3, 2025
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2025
Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
May 30, 2025
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
May 13, 2025
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 8, 2025
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
April 8, 2025
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
March 13, 2025
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
January 26, 2025
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
December 2, 2024
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
November 20, 2024
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
November 4, 2024
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting
October 14, 2024
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
September 8, 2024
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
September 2, 2024
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
July 1, 2024
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
July 1, 2024
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
July 1, 2024
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
July 1, 2024
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
May 21, 2024
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
March 27, 2024
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 6, 2024
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
March 4, 2024
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
January 7, 2024
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
January 7, 2024
First patient randomised in the phase 3 DISSOLVE clinical programme of SEL-212 for Chronic Refractory Gout
September 22, 2020